ORPHA:1489
Whooping cough
Also known as: Pertussis
Publications
104,405
99.2th percentile
Trials
299
Interventional, condition-specific
Researchers
1,328
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare bacterial infectious disease characterized by severe coughing paroxysms with inspiratory whooping and posttussive vomiting, caused by infection with Bordetella pertussis. After a variable incubation time, the clinical course progresses through a catarrhal stage with sore throat, nasal congestion, rhinorrhea, and mild dry cough, a paroxysmal stage with the typical paroxysmal coughing, and finally convalescence. Disease duration is usually 2-3 months, often with milder presentation in adolescents and adults than in infants and children.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005077
- MeSH:D014917
- UMLS:C0043167
- NCIT:C85231
Additional Mondo synonyms (6)
Bordetella pertussis caused disease or disorder · Bordetella pertussis disease or disorder · Bordetella pertussis infection · Bordetella pertussis infectious disease · pertussis · whooping cough
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
104,405 matched papers (32,165 in last 10 years) Source
- Phenotype characterisedPresent
1 HPO annotations (e.g. Whooping cough) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
299 matched on ClinicalTrials.gov (22 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
13
Drugs / clinical candidates · MONDO_0005077
- PERTUSSIS IMMUNE GLOBULIN·phase 3
- TRALOKINUMAB·phase 2
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ·approval
- BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER·approval
- BORDETELLA PERTUSSIS TOXIN·approval
- DIPHTHERIA TOXOID·approval
- ERYTHROMYCIN·approval
- ERYTHROMYCIN ETHYLSUCCINATE·approval
- HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN·approval
- PENTETIC ACID·approval
- PERTUSSIS VACCINE·unknown
- TECHNETIUM TC 99M PENTETATE·approval
- TETANUS TOXOID·approval
CTD chemicals (MyDisease.info)
1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.
- cefbuperazone · therapeutic
Literature
Is anyone studying this?
104,405
104,405 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
104,405 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
32,165 in the last 10 years · high confidence · 99.2th percentile (publications denominator)
Phrase hits: 104,405 · MeSH hits: 0
Who's working on it?
1,328
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li J7 papers · 2026
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Papers in Europe PMC - 02Zhang Y7 papers · 2026
Expanded Program Immunization Division, Shandong Center for Disease Control and Prevention,Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China.
Papers in Europe PMC - 03Wang Y6 papers · 2026
Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, 321000, China, jhzxyy.cn.
Papers in Europe PMC - 04Zhu Y6 papers · 2026
Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310000, China.
Papers in Europe PMC - 05Hariri S5 papers · 2026
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Papers in Europe PMC - 06He HQ5 papers · 2026
Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310000, China.
Papers in Europe PMC - 07He Q5 papers · 2026
European Reference laboratory for Public Health on Diphtheria and Pertussis (EURL-PH-DIPE), Turku, Finland.
Papers in Europe PMC - 08Wang J5 papers · 2026
The Center for Microbes, Development and Health, CAS Key Laboratory of Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Papers in Europe PMC - 09Wu Y5 papers · 2026
Department of Neurology, Xi'an Children's Hospital, the Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, 710003, Shaanxi, China.
Papers in Europe PMC - 10Zhang L5 papers · 2026
Expanded Program Immunization Division, Shandong Center for Disease Control and Prevention,Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
299
interventional trials for this specific condition
299 interventional trials matched this specific condition name; 22 currently recruiting in our sample.
Data as of 11 September 2026
299 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.5th percentile).
high confidence · 99.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
299 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06803524·RECRUITING·10-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Not reviewed·Conditions: Pertussis·Matched via name phrase
- NCT06184542·RECRUITING·Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
Not reviewed·Conditions: Diphtheria · Tetanus · Pertussis·Matched via name phrase
- NCT06815250·RECRUITING·Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme Trial
Not reviewed·Conditions: Vaccination Uptake · Knowledge · Tetanus, Diphtheria and Acellular Pertussis Vaccination · Influenza·Matched via name phrase
- NCT07097012·RECRUITING·Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
Not reviewed·Conditions: RSV · Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination · Pregnancy · Healthy·Matched via name phrase
- NCT07005726·ENROLLING BY INVITATION·BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Not reviewed·Conditions: Infant Morbidity · Infant Mortality · Non-Specific Effects of Vaccines · BCG·Matched via name phrase
- NCT05897879·RECRUITING·Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
Not reviewed·Conditions: Bordetella Pertussis, Whooping Cough·Matched via name phrase
- NCT06135636·RECRUITING·Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy
Not reviewed·Conditions: Non-birthing Partner Vaccination in Pregnancy · Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination · Vaccine Exposure During Pregnancy·Matched via name phrase
- NCT07203755·RECRUITING·Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
Not reviewed·Conditions: Diphtheria, Tetanus and Acellular Pertussis · Epidemic Meningitis · Haemophilus Influenzae Type B Infection·Matched via name phrase
- NCT07418372·NOT YET RECRUITING·Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
Not reviewed·Conditions: Tetanus, Diphtheria and Acellular Pertussis Vaccination · Tetanus · Diphtheria · Pertussis·Matched via name phrase
- NCT07112144·RECRUITING·Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Not reviewed·Conditions: Prevent Whooping Cough · Prevent Diphtheria · Prevent Tetanus·Matched via name phrase
- NCT06920069·NOT YET RECRUITING·Study of Concomitant Administration of the sIPV and DTaP or MMR
Not reviewed·Conditions: Polio · Diphteria, Tetanus and Pertussis · MMR Vaccine·Matched via name phrase
- NCT06997627·RECRUITING·A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Not reviewed·Conditions: Tetanus-diphtheria-acellular Pertussis (Tdap)·Matched via name phrase
- NCT07596173·RECRUITING·A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
Not reviewed·Conditions: Diphtheria-Tetanus-acellular Pertussis Vaccines·Matched via name phrase
- NCT06605755·RECRUITING·Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Not reviewed·Conditions: Pertussis · Diphtheria · Tetanus · Haemophilus Influenzae Type B Infection·Matched via name phrase
- NCT07492303·NOT YET RECRUITING·A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Not reviewed·Conditions: Pertussis (Whooping Cough) · Diphtheria · Tetanus·Matched via name phrase
Observational and natural-history studies
65 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04807712·RECRUITING·Pediatric Pertussis in Ambulatory Settings
Not reviewed·Conditions: Pertussis/Whooping Cough · Children, Only · Ambulatory·Matched via name phrase
- NCT07358910·RECRUITING·Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Not reviewed·Conditions: Dengue · Chikungunya · Zika Virus Infection · Japanese Encephalitis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 62 · after dedupe 62 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 62 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (62)
- ctis·2024-517893-73-00·Cancelled·Maternal determinants of infant immunity to pertussis (MADI-02)
skipped — LLM skipped (--skip-llm)
- ctis·2023-508416-35-00·Cancelled·A phase 4, randomised vaccination study in healthy adults to investigate the effects of acellular pertussis vaccine on colonisation with Bordetella pertussis using controlled human infection (KIM-study)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524635-39-00·Authorised·An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521752-26-00·Authorised, ongoing·A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-522406-20-00·Authorised, recruiting·A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
skipped — LLM skipped (--skip-llm)
- ctis·2023-506296-97-00·Authorised, ongoing·A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis
skipped — LLM skipped (--skip-llm)
- ctis·2023-509124-18-00·Authorised, recruiting·B7451031 - A Phase 3, Multicenter, Long-Term, Open-Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
skipped — LLM skipped (--skip-llm)
- ctis·2023-509121-51-00·Authorised, ongoing·B7451023 - A 16-Week, Multicenter, Interventional, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate Efficacy and Safety of Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
skipped — LLM skipped (--skip-llm)
- ctis·2023-507600-32-00·Authorised, recruiting·A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to
investigate the safety and immunogenicity of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers
skipped — LLM skipped (--skip-llm)
- ctis·2023-510465-10-00·Expired·A parallel-group prevention, Phase II, partially blinded, multi-stage study to investigate the immunogenicity and safety of Pentavalent Meningococcal ABCYW Vaccine formulations compared with licensed meningococcal vaccines when administered alone in healthy children (2 to 9 years of age) or concomitantly with routine pediatric vaccines in toddlers (12 to 15 months of age) and infants (2 months of age).
skipped — LLM skipped (--skip-llm)
- ctis·2024-518461-10-00·Cancelled·A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
skipped — LLM skipped (--skip-llm)
- ctis·2023-508563-73-00·Authorised·A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN-2) when 1 Dose is Administered Concomitantly with the TDaP Vaccine in Healthy Non-pregnant Women 18 to 49 years of age Compared to when Each Vaccine is Administered Alone
skipped — LLM skipped (--skip-llm)
- ctis·2024-518692-56-00·Authorised·The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women (MATIMMUNE)
skipped — LLM skipped (--skip-llm)
- ctis·2023-507906-15-00·Expired·An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
skipped — LLM skipped (--skip-llm)
- ctis·2024-510787-23-00·Cancelled·Maternal pertussis immunization in Finland, 4 years (MIFI-4Y)
skipped — LLM skipped (--skip-llm)
- ctis·2024-511478-56-00·Cancelled·dTap booster vaccination of health care workers (HC dTap)
skipped — LLM skipped (--skip-llm)
- ctis·2024-510974-25-00·Cancelled·A Phase IV, Multicenter, Open-Label Study Evaluating B-Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy – The MINORE Study
skipped — LLM skipped (--skip-llm)
- ctis·2023-506449-40-00·Cancelled·A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
skipped — LLM skipped (--skip-llm)
- ctis·2023-504331-41-00·Expired·A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and long-term safety of dupilumab in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16504454·Recruiting·A study to see if a new 6-in-1 (hexavalent) vaccine is effective and safe for babies in countries with polio
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71652721·No longer recruiting·Developing an intervention to help pregnant women decide whether to vaccinate or not
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55932023·No longer recruiting·Study of a virtual reality intervention for pain and anxiety control in pediatric vaccination
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59811905·No longer recruiting·Using parents and health workers to increase the number of children who received all the recommended childhood vaccinations without any delay in the communities of Ebonyi state, Nigeria
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN60356654·No longer recruiting·Assessing optimal timing for childhood vaccines in Uganda
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12240140·No longer recruiting·Assessing optimal timing for childhood vaccines in Nepal
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Whooping cough — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Whooping cough" OR "Pertussis" OR "Bordetella pertussis infection" OR "Bordetella pertussis infectious disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Whooping cough" OR "Pertussis" OR "Bordetella pertussis infection" OR "Bordetella pertussis infectious disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 299 interventional · 65 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: Bordetella pertussis caused disease or disorder; Bordetella pertussis disease or disorder
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T17:32:44.208Z
